SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

LXRX

Lexicon Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The EPS and revenue beats are largely non-recurring (milestone-driven). Focus shifts to Q1 2027 catalysts: SONATA-HCM topline and ZYNQUISTA NDA resubmission. Cash runway appears sufficient through these events.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

LXRX drug pipeline →

ZYNQUISTA

◆ Mixed Named in this press release
Impact
Phase
Filed/Pre-NDA resubmission (already approved as Inpefa for heart failure)
Time to market
Uncertain. NDA resubmission expected Q4 2026; if accepted, FDA has up to 6 months to review a Class 2 resubmission, meaning a potential decision in mid-2027 at the earliest.
Next catalyst
None dated

What to watchWatch for Zynquista NDA resubmission announcement in Q4 2026, that event will signal whether Lexicon believes it has adequately addressed FDA concerns. Success would be a major de-risking event; failure or further delay would be a severe blow given the company's pipeline reliance on sotagliflozin. The ~41.6% implied upside to the analyst mean price target reflects the binary nature of this catalyst.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$1.61
T+0 close · Nov 5, 2026 · via day close
Latest settled
+13.04%
T+5 · $1.82
Vs SPY
+9.75%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $1.61entry
  2. T+1 · 11d ago +10.56%α +10.25% · $1.78
  3. T+5 · 5d ago +13.04%α +9.75% · $1.82
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lexicon reported Q3 2026 net loss of $0.03 per share, narrower than the consensus estimate of -$0.05, on total revenue of $11.3M (including a $10M milestone from Novo), above the $4.1M consensus. The beat was driven by the milestone payment, not product sales; the company highlighted completion of SONATA-HCM enrollment and plans to resubmit the ZYNQUISTA NDA in Q1 2027.

Key Financial Metrics

EPS
−$0.03
est −$0.05 · +40.0%
Revenue
$11.3M
est $4.1M · +174.4% · -20.7% YoY
Rating
beat

Key Facts

  • Net loss per share -$0.03 vs consensus -$0.05 (beat)
  • Total revenue $11.3M vs consensus $4.1M (beat), driven by $10M Novo milestone
  • INPEFA net product revenue $1.2M, up from $1.0M YoY
  • Cash and investments $183.2M as of Sep 30, 2026, up from $125.2M at Dec 31, 2025
  • SONATA-HCM Phase 3 study enrolled 542 patients, top-line data expected Q1 2027
  • ZYNQUISTA NDA resubmission anticipated Q1 2027 after positive STENO1 safety data
  • LX9851 Phase 1 ongoing by Novo; Lexicon earned $75M of potential $1B milestones

Financial Impact

Net loss per share -$0.03 beat consensus by $0.02; revenue beat by $7.2M due to milestone

revenuenet losscash position

Risk Factors

  • Revenue beat is non-recurring milestone; product revenue remains modest
  • SONATA-HCM topline data in Q1 2027 is binary and could disappoint
  • ZYNQUISTA NDA resubmission outcome uncertain; FDA could request additional data
  • Operating losses continue; cash burn rate requires monitoring

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396236

Track record

16 reports on LXRX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Viewing Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
  5. Aug 6, 202614w ago 8-K Neutral 5/10 No price data
  6. Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
  7. Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
  9. May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
  10. Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026